Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.

التفاصيل البيبلوغرافية
العنوان:	Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.
المؤلفون:	Schafer, PharmD, MPH, BCPS, AAHIVP, Jason J., Pandit, Neha S, Cha, Agnes, Huesgen, Emily, Badowski, Melissa, Sherman, Elizabeth M, Cocohoba, Jennifer, Shimada, Ayako, Keith, Scott W
المصدر:	College of Pharmacy Faculty Papers
بيانات النشر:	Jefferson Digital Commons
سنة النشر:	2021
المجموعة:	Jefferson Digital Commons (Thomas Jefferson University, Philadelphia)
مصطلحات موضوعية:	Department of Pharmacy Practice, Jefferson College of Pharmacy, Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson University, adult, antiretroviral therapy, Article, cohort analysis, drug interaction, female, hormonal therapy, human, Human immunodeficiency virus, infected patient, Human immunodeficiency virus infection, male, multicenter study, retrospective study, Pharmacy and Pharmaceutical Sciences
الوصف:	Background: Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug-drug interactions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched their ART to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Methods: This was a multicenter retrospective cohort study of PWH on ART and at least 1 concomitant medication (CM) who switched to BIC/FTC/TAF between 3/2018 and 6/2019. Using the University of Liverpool's HIV Drug Interaction Database, 2 DDI analyses were performed for each patient. The first assessed patients' preswitch ART regimens with their CM list. The second assessed the same CM list with BIC/FTC/TAF. Each ART-CM combination was given a score of 0 (no or potential weak interaction), 1 (potential interaction), or 2 (contraindicated interaction). A paired Results: Among 411 patients, 236 (57%) had at least 1 DDI present at baseline. On average, baseline DDI scores (SD) were 1.4 (1.8) and decreased by 1 point (95% CI, -1.1 to -0.8) after patients switched to BIC/FTC/TAF ( Conclusions: Treatment-experienced PWH eligible to switch their ART may experience significant declines in number and severity of DDIs if switched to BIC/FTC/TAF.
نوع الوثيقة:	article in journal/newspaper
وصف الملف:	application/pdf
اللغة:	English
Relation:	https://jdc.jefferson.edu/pharmacyfp/45; https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1045&context=pharmacyfp
الاتاحة:	https://jdc.jefferson.edu/pharmacyfp/45 https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1045&context=pharmacyfp
Rights:	http://creativecommons.org/licenses/by-nc-nd/4.0/
رقم الانضمام:	edsbas.49888750
قاعدة البيانات:	BASE

View record in BASE

الوصف
الوصف غير متاح.